The Market Reports

Synopsis
The global market for Hospital-Acquired Pneumonia Prevention was estimated to be worth US$ 178 million in 2024 and is forecast to a readjusted size of US$ 276 million by 2031 with a CAGR of 6.5% during the forecast period 2025-2031.

Dental plaque is a biofilm formed by bacteria and their excreta, mainly distributed between the gums, and these bacteria cannot be removed using gauze or sponges. Bacteria in the mouth will quickly form a bacterial biofilm and cover the surface of the teeth within two hours after each cleaning. This biofilm protects common pathogens in the ICU, such as Staphylococcus aureus and Klebsiella pneumoniae. This biofilm must be destroyed before using antibacterial agents. If plaque and bacteria cannot be removed, they will move down to the balloon of the endotracheal tube. Since the balloon sealing cannot reach 100%, aspiration pneumonia will occur. Oral care is one of the effective means to prevent hospital-acquired pneumonia.

In hospitals, oral care is a vital measure to prevent aspiration pneumonia (i.e., hospital-acquired pneumonia), especially for bedridden patients, the elderly, patients with weakened immunity, and critically ill patients. This is because if the bacteria in the mouth are not effectively removed, they may enter the lungs through aspiration (i.e., swallowing saliva, food, or oral secretions), thus causing pneumonia. With the advancement of medical technology and the improvement of patients' awareness of hospital infection prevention and control, the prevention measures of hospital-acquired pneumonia have gradually gained attention. Globally, the prevention market of hospital-acquired pneumonia has gradually developed with the changes in public health needs and medical environment. The prevention market of hospital-acquired pneumonia included in this report is mainly oral care products.
Oral care products usually include oral care kits, moisturizing gels, mouthwashes, etc., among which oral care kits accounts for the largest proportion.

From the application point of view, patients in intensive care units (ICUs) are usually in an immunosuppressive state, and the risk of pneumonia infection is higher than that of patients in ordinary wards. Oral care has become an important part of reducing infection and preventing pneumonia. In order to reduce the incidence of hospital-acquired pneumonia in ICU patients, the use of oral care kits has become one of the standard preventive measures. The proportion in 2023 is approximately 60%.

The global key players of HAP prevention include Stryker, Medline, Ecolab, Avanos, Dentsply Sirona, Intersurgical and Dentaid, etc. In 2023, in term of revenue of HAP prevention, the top 3 companies hold a share nearly 43%.
The problem of antibiotic resistance is becoming more and more serious, and traditional antibiotic treatment is no longer the only way to deal with hospital-acquired pneumonia. Preventive measures, such as the use of oral care kits, can effectively reduce bacterial loads and reduce the need for antibiotics, thereby alleviating the problem of drug resistance.

This report aims to provide a comprehensive presentation of the global market for Hospital-Acquired Pneumonia Prevention, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Hospital-Acquired Pneumonia Prevention by region & country, by Type, and by Application.

The Hospital-Acquired Pneumonia Prevention market size, estimations, and forecasts are provided in terms of sales volume (M Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hospital-Acquired Pneumonia Prevention.

Market Segmentation
By Company

• Stryker
• Medline
• Ecolab
• Avanos
• Dentsply Sirona
• Intersurgical
• Dentaid
• Xttrium
• Germiphene

Segment by Type

• Oral Care Kit
• Moisturizer Gel
• Mouth Wash
• Others

Segment by Application

• General Ward
• Intensive Care Unit

Segment by Region

• North America: United States, Canada, and Mexico
• Europe: United Kingdom, Germany, France, Spain, Italy, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, and Rest of Asia Pacific
• Middle East & Africa: Saudi Arabia, South Africa, and Rest of MEA
• Latin America: Brazil, Argentina, and Rest of Latin America

*If you need a regional or country-specific version, or customized segmentation, we can tailor the report to your requirements.